Annual report [Section 13 and 15(d), not S-K Item 405]

Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details)

v3.26.1
Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - Reporting Segment [Member] - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Schedule of Reconciliation to the Consolidated Net Loss [Line Items]    
General and administrative [1] $ 7,778,869 $ 5,786,293
Pre-clinical research 378,343 1,479,896
CMC 1,887,466 1,463,530
Clinical development [1] 5,685,715 4,097,521
Depreciation and amortization 662,585
Share based compensation expense 297,467 649,029
Impairment expense 4,162,911
Other segment items [2] 3,939 773,693
Total operating and segment expenses 20,857,295 14,249,962
Reconciliation of net loss    
Change in fair value of warrant liabilities 115,301 (77,806)
Realized foreign currency translation loss from dissolution of subsidiaries (7,171)
Foreign currency gain/(loss) 30,376
Other income 380,532
Change in fair value of derivative warrant liability (416,619)  
Interest and dividends, net 327,193 423,184
Segment and consolidated net loss $ 20,427,683 $ 13,904,584
[1] includes personnel costs and excludes share-based compensation expense and impairment expense
[2] includes litigation settlements, loss from sale of assets, and loss on asset write offs